These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19469021)

  • 1. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis.
    Gao H; Lu Q; Liu X; Cong H; Zhao L; Wang H; Lin D
    Cancer Sci; 2009 Apr; 100(4):782-5. PubMed ID: 19469021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
    Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
    J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ¹H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis.
    Qi SW; Tu ZG; Peng WJ; Wang LX; Ou-Yang X; Cai AJ; Dai Y
    World J Gastroenterol; 2012 Jan; 18(3):285-90. PubMed ID: 22294833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study.
    Cox IJ; Aliev AE; Crossey MM; Dawood M; Al-Mahtab M; Akbar SM; Rahman S; Riva A; Williams R; Taylor-Robinson SD
    World J Gastroenterol; 2016 Apr; 22(16):4191-200. PubMed ID: 27122669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis.
    Nahon P; Amathieu R; Triba MN; Bouchemal N; Nault JC; Ziol M; Seror O; Dhonneur G; Trinchet JC; Beaugrand M; Le Moyec L
    Clin Cancer Res; 2012 Dec; 18(24):6714-22. PubMed ID: 23136190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry.
    Cao H; Huang H; Xu W; Chen D; Yu J; Li J; Li L
    Anal Chim Acta; 2011 Apr; 691(1-2):68-75. PubMed ID: 21458633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis.
    Yang Y; Li C; Nie X; Feng X; Chen W; Yue Y; Tang H; Deng F
    J Proteome Res; 2007 Jul; 6(7):2605-14. PubMed ID: 17564425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.
    Pasha HF; Mohamed RH; Radwan MI
    Cancer Biomark; 2019; 24(2):241-247. PubMed ID: 30689554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.
    Huang Y; Zhou S; Zhu J; Lubman DM; Mechref Y
    Electrophoresis; 2017 Sep; 38(17):2160-2167. PubMed ID: 28543513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of liver cancer from blood sera using FTIR microspectroscopy: a preliminary study.
    Thumanu K; Sangrajrang S; Khuhaprema T; Kalalak A; Tanthanuch W; Pongpiachan S; Heraud P
    J Biophotonics; 2014 Apr; 7(3-4):222-31. PubMed ID: 24639420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma.
    Lu Y; Li N; Gao L; Xu YJ; Huang C; Yu K; Ling Q; Cheng Q; Chen S; Zhu M; Fang J; Chen M; Ong CN
    Cancer Res; 2016 May; 76(10):2912-20. PubMed ID: 26976432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma.
    Noh CK; Kim SS; Kim DK; Lee HY; Cho HJ; Yoon SY; Lee GH; Hyun SA; Kim YJ; Kim HJ; Hwang JA; Ahn SJ; Shin SJ; Lee KM; Yoo BM; Cho SW; Cheong JY
    Clin Biochem; 2014 Sep; 47(13-14):1257-61. PubMed ID: 24836184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva.
    Daniels NJ; Hershberger CE; Kerosky M; Wehrle CJ; Raj R; Aykun N; Allende DS; Aucejo FN; Rotroff DM
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study.
    Assi N; Fages A; Vineis P; Chadeau-Hyam M; Stepien M; Duarte-Salles T; Byrnes G; Boumaza H; Knüppel S; Kühn T; Palli D; Bamia C; Boshuizen H; Bonet C; Overvad K; Johansson M; Travis R; Gunter MJ; Lund E; Dossus L; Elena-Herrmann B; Riboli E; Jenab M; Viallon V; Ferrari P
    Mutagenesis; 2015 Nov; 30(6):743-53. PubMed ID: 26130468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Untargeted metabolomics of blood plasma samples of patients with hepatocellular carcinoma.
    Böhmová A; Mikoška M; Syslová K; Šindelářová D; Hříbek P; Urbánek P; Setnička V
    J Pharm Biomed Anal; 2024 Sep; 248():116263. PubMed ID: 38852296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T
    Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.